Medincell Sa Stock Price To Sales

MDCLF Stock  USD 6.98  0.00  0.00%   
MedinCell SA fundamentals help investors to digest information that contributes to MedinCell's financial success or failures. It also enables traders to predict the movement of MedinCell Pink Sheet. The fundamental analysis module provides a way to measure MedinCell's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to MedinCell pink sheet.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

MedinCell SA Company Price To Sales Analysis

MedinCell's Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.

P/S

 = 

MV Per Share

Revenue Per Share

More About Price To Sales | All Equity Analysis

Current MedinCell Price To Sales

    
  31.58 X  
Most of MedinCell's fundamental indicators, such as Price To Sales, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, MedinCell SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
Competition

Based on the latest financial disclosure, MedinCell SA has a Price To Sales of 31.5781 times. This is 47.56% higher than that of the Healthcare sector and 67.91% lower than that of the Biotechnology industry. The price to sales for all United States stocks is 176.52% lower than that of the firm.

MedinCell Price To Sales Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses MedinCell's direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of MedinCell could also be used in its relative valuation, which is a method of valuing MedinCell by comparing valuation metrics of similar companies.
MedinCell is currently under evaluation in price to sales category among its peers.

MedinCell Fundamentals

About MedinCell Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze MedinCell SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of MedinCell using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of MedinCell SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

Other Information on Investing in MedinCell Pink Sheet

MedinCell financial ratios help investors to determine whether MedinCell Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in MedinCell with respect to the benefits of owning MedinCell security.